Kei Takigawa

Background: Immune checkpoint inhibitors (ICIs) are used to treat several malignancies but predispose to systemic autoimmune inflammation referred to as immune-related adverse events (irAE). Upper and lower gastrointestinal (GI) tract inflammation are commonly encountered toxicities…